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Studies in the recent years have advanced the knowledge of how host and parasite fac-
tors contribute to the pathogenesis of human tegumentary leishmaniasis. Polymorphism
within populations of Leishmania from the same species has been documented; indicat-
ing that infection with different strains may lead to distinct clinical pictures and can also
interfere in the response to treatment. Moreover, detection of parasite genetic tags for the
precise identiﬁcation of strains will improve diagnostics and therapy against leishmaniasis.
On the host side, while a predominant Th1 type immune response is important to control
parasite growth, it does not eradicate Leishmania and, in some cases, does not prevent
parasite dissemination. Evidence has accumulated showing the participation of CD4+ and
CD8+ T cells, as well as macrophages, in the pathology associated with L. braziliensis,
L. guayanensis, and L. major infection.The discovery that a large percentage of individuals
that are infected with Leishmania do not develop disease will help to understand how the
host controls Leishmania infection. As these individuals have a weaker type 1 immune
response than patients with cutaneous leishmaniasis, it is possible that control of para-
site replication in these individuals is dependent, predominantly, on innate immunity, and
studies addressing the ability of neutrophils, macrophages, and NK cells to kill Leishmania
should be emphasized.
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INTRODUCTION
Tegumentary leishmaniasis (TL), caused by protozoan parasites of
the genus Leishmania, is a major health problem in many regions
of the world. After been transmitted by sand ﬂies, Leishmania
parasites infect human macrophages and dendritic cells (DCs),
causing a wide spectrum of clinical manifestations, including self-
healing skin lesions, cutaneous leishmaniasis (CL), disseminated
leishmaniasis (DL),mucosal leishmaniasis (ML), and diffuse cuta-
neous leishmaniasis (DCL). Around 10% of individuals living
in L. braziliensis transmission areas have evidence of exposure
to Leishmania, as determined by a positive Leishmania skin test
(LST), but do not develop disease (sub-clinical infection). Host,
parasite, and vector factors participate in the pathogenesis of
leishmaniasis. More than 20 species of Leishmania cause human
disease and CL is the most common clinical picture of TL. In
the Old World the most important species are L. major, L. trop-
ica, and L. aethiopica, and in the New World, L. braziliensis,
L. amazonensis,L.mexicana,L. guyanensis, andL. panamensis. This
review will address the role of parasites, and innate and adaptive
immunological responses in the pathogenesis of TL.
PARASITE FACTORS IN TEGUMENTARY LEISHMANIASIS
Productive infections with Leishmania spp result in visceral or sev-
eral tegumentary disorders (Murray et al., 2005). This reﬂects the
substantial variability among the etiological agents at the sub-
genus level with many species described as human pathogens,
which may be subdivided into the Leishmania Leishmania sub-
genus that comprises the L. tropica, L. donovani, and L. mexicana
complexes of species, and the subgenus Leishmania Viannia that
consists in the L. braziliensis complex of species (Thomaz-Soccol
et al., 1993a,b; Shaw, 1994; Croan et al., 1997). Many, if not all,
of these species present a high degree of intra-species genetic and
phenotypic polymorphism, which is accompanied by a spectrum
of clinical presentations in the infected human host. For exam-
ple, an ample variability has been reported for L. braziliensis (Kahl
et al., 1991; Gomes et al., 1995; Saravia et al., 1998, 2002; Ishikawa
et al., 2002; Cupolillo et al., 2003; Schriefer et al., 2004), which
causes at least three well documented forms of TL: CL, ML, and
the emerging DL (Costa et al., 1986; Carvalho et al., 1994b; Azulay
and Azulay Júnior, 1995; Turetz et al., 2002; Guerra et al., 2011).
Although a thorough understanding of the mediators of infec-
tion outcome is lacking, some mechanisms have been unveiled.
Parasite persistence due to evasion of immunity is one factor inﬂu-
encing disease duration and clinical outcome toward more severe
forms of leishmaniasis, in part through arginine metabolism.
Depending on the type of arginase that the host cell expresses, argi-
ninemetabolismmay result in theproductionof nitric oxide (NO),
or in L-ornithine. NO is toxic for the parasite, while L-ornithine
is essential for Leishmania growth (Iniesta et al., 2001). Besides,
the parasite’s own arginase was shown to inﬂuence infectivity.
L. mexicana knocked out for arginase activity led to signiﬁ-
cantly attenuated infection of mice and had poorer survival inside
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macrophages than the wild type strain (Gaur et al., 2007). This
seems in concordance with reports which show that the insulin-
like growth factor one promotes in vivo and in vitro growth of
different species of Leishmania, at least in part, by activating
arginase (Vendrame et al., 2007). A possible clinical expression
of these ﬁndings may be the observation that promastigotes of
L. amazonensis and L. braziliensis that are resistant to NO in vitro
are associated with poorer outcomes of the patients they were
isolated from (Giudice et al., 2007).
Different reports indicate that parasite resistance to hydrogen
peroxidemay also play a role inmore severe formsof leishmaniasis.
Clones of L. guyanensis capable of metastasization in golden ham-
sters present cytoplasmic peroxiredoxin and peroxidase activities
different from those of non-metastatic parasites (Acestor et al.,
2006), while laboratory strains of L. guyanensis with metastatic
phenotype present isoforms of tryparedoxin peroxidase and elon-
gation factor-1 beta different from those of non-metastatic strains
(Walker et al., 2006). Two reports described an increased fre-
quency of mucosal involvement among human cases caused by
certain L. braziliensis strains in Colombia (Saravia et al., 1998,
2002). Length of cutaneous disease in those infected with par-
asites of a “mucosal-prone” L. braziliensis zymodeme was also
signiﬁcantly longer than that caused by other strains (Saravia et al.,
2002). Another study performed in one of the regions with great-
est endemicity for ATL in Brazil described a complex population
of L. braziliensis made up of several different clones of the par-
asite affecting leishmaniasis patients and detected a statistically
signiﬁcant association between parasite genotype and clinical out-
comes toward CL, ML, or DL (Figure 1; Schriefer et al., 2004).
Interestingly, a follow-up study in the same region identiﬁed that
the distribution of ML and DL, which are more aggressive forms
of TL, differed signiﬁcantly across the affected area and that geo-
graphic distribution of TL forms also seemed to be inﬂuenced by
the strain of L. braziliensis (Schriefer et al., 2009). Nevertheless,
the most compelling putative mechanism leading to ML involves
the infection of L. guyanensis strains with the Leishmania RNA
virus-1 (LRV-1; Ives et al., 2011). In experimental mice, the metas-
tasizing L. guyanensis parasites presented higher LRV-1 burden
than non-metastasizing strains. It was found that the increased
LRV-1 burden stimulated the host Toll-like receptor 3 (TLR3) and
induced pro-inﬂammatory cytokine and chemokine production
by the macrophages. If this mechanism overlaps what occurs in
human disease pathology, it would ultimately result in the strong
inﬂammatory response and tissue destruction observed in the ML
patients.
INNATE IMMUNE RESPONSE IN HUMAN TEGUMENTARY
LEISHMANIASIS
The development of a protective immune response to intracel-
lular pathogens requires the coordinated action of cells from
FIGURE 1 | Parasite and host factors contribute to disease outcome in
human L. braziliensis infection. Parasite polymorphisms are associated with
clinical forms of the disease. The type of immune response developed by the
host, determine whether parasite growth will be controlled or dissemination
will occur. Detection of Leishmania in blood from SC individuals has not been
achieved. Exaggerated pro-inﬂammatory immune response leads to tissue
damage and ulcer development. Cells known to contribute to cytokines and
CXCL9 production in L. braziliensis-infected patients are represented below
the corresponding soluble factor. CL, cutaneous leishmaniasis; ML, mucosal
leishmaniasis; DL, disseminated leishmaniasis; SC, sub-clinical.
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innate and adaptive immunity. After Leishmania infection, dif-
ferent cell types of the innate immune response can inter-
act with the parasite. Although macrophages are the major
host cells for Leishmania, reports using animal models have
shown that neutrophils and DCs are also able to uptake Leish-
mania parasites early after infection. Neutrophils provide an
important link between innate and adaptive immunity during
parasitic infections. These cells can interact with monocytes,
DCs, and T and B lymphocytes through cell–cell contact or
secreted products, driving inﬂammatory responses involved in
host defense and tissue repair (Nathan, 2006; Charmoy et al.,
2010). Cooperation between neutrophils and macrophages con-
tributes to both resistance and susceptibility to Leishmania infec-
tion in experimental models. Thus, neutrophils from BALB/c
mice induce intramacrophagic killing of L. braziliensis, which
was dependent on TNF and reactive oxygen species (Novais
et al., 2009). Also, phagocytosis and elimination of Leishma-
nia amastigotes by neutrophils was shown in the later stages
of the disease (Daboul, 2010). Neutrophils have a short life
span and are constitutively programmed to die by apoptosis.
Clearance of apoptotic cells by macrophages is associated with
anti-inﬂammatory mediators such as TGF-beta and PGE2, which
inhibit macrophage activation (Voll et al., 1997; Fadok et al.,
1998), whereas, phagocytosis of necrotic neutrophils induces
macrophage activation through production of pro-inﬂammatory
mediators (Savill, 2000). The effect of human necrotic and apop-
totic neutrophils in response to L. amazonensis infection was
investigated. It was observed that apoptotic, but not viable, neu-
trophils increased the parasite burden through a mechanism
dependent onTGF-beta and PGE2. In an opposite way, interaction
of necrotic neutrophils with L. amazonensis-infected macrophages
decreased the infection rate as well as the parasite burden
(Afonso et al., 2008).
Classically activated macrophages secrete IL-12, produce oxy-
gen reactive species and are the main cells involved in intracellular
parasite killing, whereas alternatively activated and regulatory
macrophages are permissive to parasites growth (Mosser and
Zhang, 2008; Wanasen and Soong, 2008; Martinez et al., 2009).
Although classically activated macrophages have leishmanicidal
machinery, some species of Leishmania parasites have devel-
oped ways to escape immune events (Mosser and Zhang, 2008).
For instance, studies have shown that L. braziliensis infection of
macrophages lead to proteasome-mediated degradation of STAT-
1, production of regulatory cytokine, TGF-beta, and impairment
in adhesion to extracellular matrix (Barral et al., 1993; Forget
et al., 2005; Pinheiro et al., 2006). However, these in vitro studies
are quite contradictory with the in vivo scenario of L. brazilien-
sis-infected patients, where exaggerated inﬂammatory response
is observed and low amounts of parasites are detected. Dif-
ferences in macrophage responses to Leishmania parasites have
been documented. For example, macrophages from individ-
uals with sub-clinical infection control parasite growth more
efﬁciently than macrophages from CL patients as observed in
human L. braziliensis infection (Bosque et al., 1998; Giudice et al.,
2012), pro-inﬂammatory chemokines, such as CCL2, CXCL-
9, and CXCL-10, secreted predominantly by macrophages, are
higher in CL and ML than in individuals with SC L. braziliensis
infection. As these molecules activate and recruit macrophages
and T cells to the lesion site, they may participate in the
pathology.
NKcells represent one of theﬁrst lines of defense in the immune
reaction after invasion of Leishmania parasites. Those cells can
produce IFN-γ that will activate macrophages to kill Leishmania.
Absence or low number of NK cells, and impairment of NK cells
response were documented in lesions from patients with CL. The
possible explanation for this result, can be the fact that direct con-
tact points found between Leishmania promastigotes and naïve
humanNKcells causes immediate destructionof NKcells in anon-
apoptotic way (Lieke et al., 2011). In this context, a role for gp63
in inhibition of human NK cells proliferation has been demon-
strated (Lieke et al., 2011). Indirect evidence of the role of NK
cells to the protective immune response against Leishmania come
from the observation that, in individuals with SC infection as well
as individuals without exposure to Leishmania, NK cells is the
main source of IFN-γ upon stimulation in vitro with L. aethiopica
(Maasho et al., 1998; Nylen et al., 2003).
In leishmaniasis a large variety of cells contribute to the pro-
duction of IL-10, including DCs and macrophages. While IL-10
plays an important role in down regulating Th1 immune response,
decreasing lymphocyte proliferation and production of IFN-γ in
patients with visceral leishmaniasis (Carvalho et al., 1994a; Nylen
and Sacks, 2007), the role of IL-10 in the pathogenesis of TL is not
so clear. IL-10 facilitates parasite growth and it may play an impor-
tant role in the initial phase of Leishmania infection, contributing
to the establishment of the parasite. As most of the studies eval-
uating the role of IL-10 in leishmaniasis are related to its indirect
effects in T cells function, this subject will be discussed later in the
section of adaptative immune response.
Dendritic cells are essential for an effective immune response
against most pathogens. Prior to infection, DCs survey the tissues
and the lymphoid organs as “immature” cells. Leishmania killing
process, require that DCs uptake Leishmania and Leishmania anti-
gens, migrate to lymph nodes, present antigen and prime T cells to
produce IFN-γ. For efﬁciently present antigen, DC has to undergo
through a maturation program, which includes up-regulation of
molecules such as MHC II, CD80, and CD86 and production
of pro-inﬂammatory cytokines such as IL-12 and TNF. In order
to avoid activation of cells from adaptative immune response,
Leishmania have developed mechanisms to inhibit DC function.
Many works have been performed using mouse DCs and conﬂict-
ing results have been published regarding ability of Leishmania
to inhibit these cells functions. While some studies documented
mononuclear phagocytes activation upon Leishmania infection,
others did not see change on activations markers (De Trez et al.,
2004; Sanabria et al., 2008). In vitro single cell-based analysis have
revealed that while Leishmania-infected DCs remains immature,
bystander ones up-regulate MHC II and costimulatory molecules
(Carvalho et al., 2008). Investigations using human cells have doc-
umented that certain primary human DC subsets obtained ex vivo
uptake Leishmania and release IL-12. This is in contrast to prior
studies indicating that human DC do not contribute to primary
immunity against Leishmania (Marovich et al., 2000; McDowell
et al., 2002; Favali et al., 2007; Revest et al., 2008; Griewank et al.,
2010). The discrepancy between these studies may have to do with
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different parasite species and life-cycle stages, as well as different
sources of cells used.
CELL-MEDIATED IMMUNE RESPONSE IN HUMAN
TEGUMENTARY LEISHMANIASIS
Since the early studies in cell-mediated immune response to intra-
cellular pathogens in the beginning of the 80s, much progress
has been made for the understanding of how host ﬁght Leish-
mania pathogens. Works using mouse models, intent to elu-
cidate immune events important for Leishmania killing, have
revealed that reactive oxygen species produced by IFN-γ-activated
mononuclear phagocytes, is the main mechanism used by infected
macrophages to destroy Leishmania. Thus, while in BALB/c mice
infected with L. major Th2 immune response prevails allowing
parasites to multiplicate, C57BL/6 mice are able to control infec-
tion with strong Th1 immune response. In humans, the Th1/Th2
paradigm does not quite explain the natural outcome of the dis-
ease. TL patients may present different clinical forms of diseases
with distinct pattern of immune response. Clinically, patients may
develop single or multiple cutaneous ulcers, nodular, papular, or
acneiform lesions, and although Th1 responses be the desired for
parasite killing, number of lesions is not associatedwith the type of
immune response developed after infection. For example, patients
infected with L. amazonensis may develop DCL, a disease char-
acterized by the presence of many nodular lesions. Lymphocytes
from DCL patients do not produce IFN-γ upon in vitro stimuli
with Leishmania antigen, which is associated with parasite pro-
liferation and dissemination along the body of these individuals.
Differently, individuals infected with L. braziliensis, may develop
an emerging form of leishmaniasis, also with multiple lesions
denominated DL. In these individuals high production of TNF
and IFN-γ is documented, both in blood and tissue, and they
develop ulcerative lesions similar to that observed in CL and ML
(Figure 1; Machado et al., 2011). Therefore, while in the absence of
Th1 immune response, as observed in DCL, parasite multiply and
disseminate, an exaggerated type 1 immune response is observed
in patients with DL, CL, and ML. However, as Leishmania is not
eradicated the tissue damage in these forms of leishmaniasis is
associated with the inﬂammatory reaction.
It is quite difﬁcult to evaluate human immune response
early after Leishmania infection. Studies in an endemic area of
L. braziliensis transmission have documented that before cuta-
neous ulcer develops, lymphadenopathy is observed in most cases
(Barral et al., 1995). In a few weeks, a papular or exulcerative lesion
appears. Biopsy of these initial lesions showed that parasites are
present, although in very low numbers, and mononuclear cells
start to inﬁltrate as angiogenesis occurs. During this phase IFN-
γ levels are low, but signiﬁcant amount of TNF can be observed
in Leishmania antigen-stimulated peripheral blood mononuclear
cells (PBMCs) supernatants (Rocha et al., 1999; Unger et al., 2009).
Inﬂammatory inﬁltrate composed, predominantly, by mononu-
clear phagocytes, T and B lymphocytes and plasma cells, is already
documented and increases as ulceration develops. The low pro-
duction of pro-inﬂammatory cytokines in the early phase of CL
is due, in part, to presence of IL-10, as neutralization of this
cytokine enhances IFN-γ production (Rocha et al., 1999). Usually,
1–2 weeks after the appearance of the papule and exulceration,
a classic CL ulcer is observed. Development of the classical ulcer
coincides with a great increase in TNF and IFN-γ and low levels
of IL-10 (Bacellar et al., 2002; Unger et al., 2009). High amounts
of IFN-γ and TNF are observed in both, Leishmania antigen-
stimulated PBMC cultures, and in the ulcer of CL patients. The
levels of inﬂammatory cytokines inLeishmania antigen-stimulated
PBMC cultures from patients with ML, is even higher than those
documented in CL (Bacellar et al., 2002; Carvalho et al., 2007).
This is also true at lesion site (Faria et al., 2005). Evidences for
the contribution of TNF for immunopathology in TL, has been
accumulated: (1) there is a positive correlation between lesion
size and TNF levels in PBMC cultures stimulated with Leish-
mania antigen (Antonelli et al., 2005); (2) TNF levels fall after
therapy of CL and ML (Da-Cruz et al., 2002); (3) Patients treated
with pentavalent antimonial combined with pentoxifylline, a TNF
inhibitor, have a better rate of cure than those treated with pen-
tavalent antimonial alone (Lessa et al., 2001; Machado et al., 2002);
(4) Pentoxifylline combined with antimony therapy cure CL and
ML patients refractory to antimony therapy (Lessa et al., 2001;
Baﬁca et al., 2003).
The enhanced IFN-γ and TNF production in CL and ML is
not due to absence of IL-10. Although low amounts of IL-10 are
found in supernatants fromLeishmania antigen-stimulatedPBMC
from CL and ML individuals, studies in lesions of these patients
have documented presence of IL-10-secreting macrophages and
regulatory T cell (CD4+CD25+Foxp3+; Campanelli et al., 2006;
Bourreau et al., 2009; Faria et al., 2009). The participation of regu-
latoryT cells in the regulationof immune response in experimental
leishmaniasis has been intensively investigated. IL-10 secreted by
Tregs are involved in persistence of parasites, regulation of Th2
cell expansion, and control of cell-mediated lesion development
in leishmaniasis (Powrie et al., 1994; Sacks and Kamhawi, 2001;
Aseffa et al., 2002; Xu et al., 2003; Mendez et al., 2004; Ji et al.,
2005). Regulatory T cells isolated from lesion from CL patients
infected with L. braziliensis and L. guyanensis were able to inhibit
proliferation of T cells to polyclonal and Leishmania antigen stim-
uli (Campanelli et al., 2006,2010; Bourreau et al., 2009). In human,
an obvious question to be addressed has to do with the discrep-
ancy between presence of IL-10 in tissue and lack of regulation
of inﬂammatory response in ML. One explanation would be that
cells arriving at lesion site have already effector characteristics,
and can no longer be modulated by the effects of IL-10. In ML,
lack of response to IL-10 can be in part explained by the down-
regulation of IL-10 receptor, as lesions from ML patients have
a decrease in the number of cells expressing IL-10 receptor and
a decrease in the intensity of expression of this receptor when
compared with CL patients (Faria et al., 2005). However, studies
have to be performed for the better understanding of the dynamic
of IL-10 receptor expression in uninfected controls as well as in
leishmaniasis patients in response to Leishmania antigens. IL-27
is a regulatory cytokine of interest in infectious disease. Although
initial studies have identiﬁed IL-27 as an inﬂammatory cytokine
since it can promote Th1 responses by enhancing T-bet expres-
sion in CD4+ T cells, later reports have shown that IL-27 can
down-regulate T cell activity both, dependent and independent
of IL-10 demonstrated in human visceral leishmaniasis (Hunter
et al., 1994; Ansari et al., 2011). Expression of IL-10 and IL-27
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were similar in CL patients and in individuals with sub-clinical
L. braziliensis infection (Novoa et al., 2011).
The attempt to down-regulate Leishmania antigen-induced
IFN-γ production in ML using in vitro monoclonal antibody to
IL-12 or IL-15, failed, suggesting that patients with ML have a
portion of T cell population fully differentiated that no longer
depends on these cytokines to differentiate/survive and induce
inﬂammation. In fact, the ex vivo analysis of peripheral blood
reveled that ML patients have increased population of CD4+ T
cells expressing CD69, CD25, and CD62Ldim, when compared to
CL individuals (Gaze et al., 2006; Carvalho et al., 2007). It is well
known that the magnitude of inﬂammatory response can be inﬂu-
enced by host genetic. For example, familial aggregation in ML has
been documented and polymorphisms of genes encoding inﬂam-
matory proteins (cytokines and chemokines) are associated with
CL and ML (Castellucci et al., 2011). As mentioned before, par-
asite genetic factors also interfere on inﬂammatory responses, as
Leishmania antigens isolated from CL patients induces more TNF
and IFN-γ production than those from DL patients (Castellucci
et al., 2006; Leopoldo et al., 2006).
CD8+ T cells are predominantly recognized by its cytotoxic
characteristics, but they can also have regulatory properties. In
mice, CD8+ T cell play an important role in the protection against
Leishmania infection (Wang et al., 1993). In lesions of CL patients
infected with L. guayanensis, CD8+ T cells expressing IL-10 are
documented (Bourreau et al., 2009). Thus, it is possible that
although IL-10 is not able to control the exaggerated inﬂamma-
tory response, it does facilitate the maintenance of parasites in
tissue. CD8+ T lymphocytes kill L. braziliensis-infected cells in
vitro, and killing was greater in ML patients than in CL patients
(Brodskyn et al., 1997). However, as Leishmania persists in CL
and ML patients despite the presence of CD8+ T cells and these
cells also produce pro-inﬂammatory cytokines, it is possible that
they also participate in the pathology, by killing epithelial cells
that expresses Leishmania antigen. In favor of this hypothesis, it
has been shown that the frequency of CD8+ T cells expressing
granzyme in tissue of CL patients is higher when compared to
patients in the early phase of CL, and that the frequency of CD8+ T
cells expressing granzyme, is directly associated with the intensity
of the inﬂammatory reaction in CL ulcers (Faria et al., 2009).
Several studies have established a role for IL-17 in susceptibility
or protection to intracellular parasites infections. In a susceptible
mouse model for L. major, absence of IL-17 resulted in smaller
lesions (Lopez Kostka et al., 2009). Differently, in L. braziliensis
mouse model of leishmaniasis, self-healing lesions were associ-
ated with presence of IL-17 (Vargas-Inchaustegui et al., 2008). In
humans, IL-17 has been found in lesions of CL and ML patients
and PBMC from these individuals produce this cytokine in
response to Leishmania antigen (Bacellar et al., 2009; Boaventura
et al., 2010). However, IL-17 was not associated with pathology as
determined by lesion size or presence of mucosal disease (Bacel-
lar et al., 2009). In other infectious diseases, the main function
of IL-17 is to, indirectly, recruit neutrophils to inﬂammatory site
(Charmoy et al., 2007). However, in spite of the presence of IL-17
in lesion of L. braziliensis-infected individuals, the majority of the
studies have documented mononuclear cells inﬁltrate in lesion of
CL and ML. Importantly, a recent report showed neutrophils in
lesion of ML patients, suggesting that these cells may play a role
in tissue damage in ML (Boaventura et al., 2010). Different from
patientswithCL andML, individualswith sub-clinicalL. brazilien-
sis infection produce low amounts of IFN-γ and TNF (Follador
et al., 2002), are able to kill Leishmania and do not develop disease.
The low production of pro-inﬂammatory cytokines in SC infec-
tion is not due to regulatory mechanisms mediated by IL-10 and
IL-27 (Novoa et al., 2011). In contrast with the low production
of TNF, these individuals produce IL-17 levels similar to the ones
observed in CL and ML patients (Novoa et al., 2011). As IL-17
has been associated with protection in VL (Pitta et al., 2009). It is
important to determine if this cytokine play a role in the control
of TL.
PARASITE AND HOST FACTORS IN THERAPY FOR
TEGUMENTARY LEISHMANIASIS
There are a large variety of therapies for TL, that includes local
treatments as cryotherapy, thermotherapy and local antigens
application, and systemic therapies, being the more common pen-
tavalent antimonials, pentamidine and liposomal amphotericin
B. While the efﬁcacy of local therapies was documented in infec-
tions with L. major, L. tropica, and L. mexicana, pentamidine is
the drug of choice for L. guyanensis, and pentavalent antimoni-
als for L. braziliensis infection. It has been well documented that
patient response to antimonials varies according to the species of
the parasite they are infected with, and even responses to drugs
to parasite species belonging to the same complex can be hetero-
geneous (Arevalo et al., 2007). It has been shown that sensitivity
of L. braziliensis promastigotes to antimony is greater than that
of other species of the same complex (Azeredo-Coutinho et al.,
2007). However, to underscore the complexity of this issue the
infection with L. braziliensis and L. peruviana was found to be
a risk factor for antimony failure in Peru (Llanos-Cuentas et al.,
2008), and different reports show that the efﬁcacy of these drugs
vary even within a single species like L. braziliensis (Saldanha et al.,
1999; Andersen et al., 2005).
A growing literature reveals that Leishmania spp. are able to
develop resistance to antimony, which is abroad used drug to
treat leishmaniasis patients. The occurrence of resistant strains
and of cases failing treatment due to parasite variants has been
reported in highly affected countries, like Iran (Hadighi et al.,
2006), Peru (Llanos-Cuentas et al., 2008), and Brazil (Arevalo
et al., 2007; Azeredo-Coutinho et al., 2007), involving species as
diverse as L. tropica, L. donovani, and L. braziliensis (Hadighi et al.,
2006; Arevalo et al., 2007; Azeredo-Coutinho et al., 2007; Samant
et al., 2007; Llanos-Cuentas et al., 2008). The phylogenetic distance
among these species suggest that these parasites must be capable
of adapting for drug pressure by diverse mechanisms.
Although detailed description of drug resistance mechanisms
is still scarce for this genus, the detection of parasite markers for
drug resistance/susceptibility phenotypes seems to be an attain-
able goal. In one such case, it has been shown that a group of
glycoproteins collectively called proteophosphoglycans (PPGs) is
overexpressed on the surfaces of promastigotes and amastigotes
of stibogluconate-resistant ﬁeld isolates of L. donovani from India
(Das Gupta et al., 1991; Samant et al., 2007). Although the role
PPGs may play in the mechanism of resistance is unknown, the
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authors pointed out that their overexpression could be explored
as a phenotypic marker of likely drug resistance among parasites
isolated with diagnostic purposes.
In addition to parasites factors, host immunologic factors are
also important for therapy in TL. Patients with DCL, the anergic
form of TL, have impairment in the Th1 type immune response
to Leishmania antigens and failed to all forms of therapy or
relapse after apparent successful therapy. In one report, the use of
recombinant IFN-γ associated with antimony induced cure in VL
patients (Badaro et al., 1990). Thus, this may also consist in a can-
didate therapy for better managing DCL. A better understanding
of the immunologic mechanisms of tissue damage in leishmani-
asis may also help to improve the management of leishmaniasis.
Granulocyte colony stimulate factor (GM-CSF) improves antigen
presentation and also down modulate the exaggerated inﬂamma-
tory response in CL. Topical or systemic GM-CSF associated with
antimonial therapy is more effective than antimony alone and cure
CLpatients refractory to antimonial therapy (Almeida et al., 2005).
The documentation that TNF plays a pivotal role in tissue dam-
age in Leishmania infection, have led to use of pentoxifylline as
adjuvant therapy in CL and ML. Pentoxifylline down-modulates
TNF as well as pro-inﬂammatory chemokines, and when associ-
ated with antimony therapy is more effective than antimony alone,
accelerating healing time of CL and ML and curing CL and ML
patients refractory to antimony therapy (Lessa et al., 2001; Baﬁca
et al., 2003; Machado et al., 2007).
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